Ascletis Clears FDA Hurdle for Once-Monthly Obesity Drug ASC35
Event summary
- Ascletis received FDA IND clearance for Phase I trial of ASC35, a once-monthly subcutaneous GLP-1R/GIPR dual agonist for obesity treatment.
- Phase I trial includes two parts: single ascending dose study and head-to-head comparison with tirzepatide's weekly formulation.
- Preclinical data shows ASC35 has six-fold longer half-life than tirzepatide in non-human primates and 71% greater weight loss efficacy in diet-induced obese mice.
- ASC35 uses proprietary SALD formulation for extended drug release, potentially improving patient compliance.
The big picture
Ascletis' FDA clearance for ASC35 comes as the obesity drug market continues to expand, with increasing demand for more convenient and effective treatments. The company's proprietary technologies aim to differentiate its pipeline in a competitive landscape dominated by weekly injection therapies. Success in this Phase I trial could position Ascletis as a significant player in the long-acting obesity treatment space.
What we're watching
- Clinical Superiority
- Whether ASC35's preclinical advantages in half-life and efficacy will translate to human trials.
- Market Differentiation
- How Ascletis positions ASC35 against established weekly formulations like tirzepatide.
- Pipeline Progression
- The pace at which Ascletis advances its other obesity treatment candidates through development.
Related topics